Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Glimepiride,Dapagliflozin,Metformin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mascot Sets New Diabetes Care Standard with DCGI-Approved Dapagliflozin FDC
Details : Dapagliflozin, metformin and glimepiride fixed dose combination is approved for the treatment of patients with type 2 diabetes.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 11, 2023
Lead Product(s) : Glimepiride,Dapagliflozin,Metformin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glimepiride,Metformin,Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mascot Health Series gets DCGI Nod for Triple Combination Diabetes Medication
Details : Sitagliptin, metformin and glimepiride fixed dose combination is approved for the treatment of patients with type 2 diabetes.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 07, 2023
Lead Product(s) : Glimepiride,Metformin,Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable